TuHURA Reports Partial Responses in First Three IFx-2.0 Trial Patients
TuHURA reports partial responses in the first three patients in its IFx-2.0–Keytruda Merkel cell carcinoma trial.
TuHURA reports partial responses in the first three patients in its IFx-2.0–Keytruda Merkel cell carcinoma trial.